00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: V-region immunoglobulin-containing suppressor of T cell activation (VISTA); programmed cell death 1 (PD-1; PDCD1; CD279); programmed cell death 1

Cancer INDICATION: Cancer Mouse studies suggest combining mAbs against VISTA and PD-1 or PD-L1 could help treat cancer. In mice, double-knockout of VISTA and PD-1 increased T cell responses to non-self antigens compared with single-knockout of either...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer V-region immunoglobulin-containing suppressor of T cell activation (VISTA) Cell culture and mouse studies suggest inhibiting VISTA...
08:00 , Nov 5, 2012 |  BioCentury  |  Emerging Company Profile

ImmuNext: New VISTAs

ImmuNext Inc. has developed an antagonist of VISTA, a ligand that negatively regulates T cells similar to better known members of the B7 family of proteins. But targeting VISTA could be safer than targeting other...